Bio-View Ltd
Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company's products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatic… Read more
Bio-View Ltd (BIOV) - Total Liabilities
Latest total liabilities as of June 2025: ILA8.26 Million ILA
Based on the latest financial reports, Bio-View Ltd (BIOV) has total liabilities worth ILA8.26 Million ILA as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bio-View Ltd - Total Liabilities Trend (2009–2024)
This chart illustrates how Bio-View Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bio-View Ltd Competitors by Total Liabilities
The table below lists competitors of Bio-View Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xunlei Ltd
STU:4XN
|
Germany | €134.74 Million |
|
MANITEX INTL
BE:VE8
|
Germany | €164.62 Million |
|
ADF GROUP SBVTG
BE:4QM
|
Germany | €140.56 Million |
|
Dividend Growth Split Corp
TO:DGS
|
Canada | CA$497.51 Million |
|
SUNOPTA
MU:ZSK
|
Germany | €538.07 Million |
|
Sporttotal AG
F:WIG1
|
Germany | €50.80 Million |
|
Start Today Co. Ltd
STU:SAR
|
Germany | €77.40 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Bio-View Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bio-View Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bio-View Ltd (2009–2024)
The table below shows the annual total liabilities of Bio-View Ltd from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ILA10.68 Million | -27.12% |
| 2023-12-31 | ILA14.65 Million | +7.31% |
| 2022-12-31 | ILA13.65 Million | +6.18% |
| 2021-12-31 | ILA12.86 Million | +45.77% |
| 2020-12-31 | ILA8.82 Million | -26.70% |
| 2019-12-31 | ILA12.03 Million | +12.88% |
| 2018-12-31 | ILA10.66 Million | -5.30% |
| 2017-12-31 | ILA11.26 Million | +1.39% |
| 2016-12-31 | ILA11.10 Million | +6.85% |
| 2015-12-31 | ILA10.39 Million | -19.72% |
| 2014-12-31 | ILA12.94 Million | +6.16% |
| 2013-12-31 | ILA12.19 Million | -7.14% |
| 2012-12-31 | ILA13.13 Million | -8.26% |
| 2011-12-31 | ILA14.31 Million | +7.74% |
| 2010-12-31 | ILA13.29 Million | +1.23% |
| 2009-12-31 | ILA13.12 Million | -- |